isabelobrien, Author at European Medical Journal - Page 5 of 65

ABPI calls for NICE cost-effectiveness threshold review

ABPI calls for NICE to raise its cost effectiveness threshold for new medicine, which hasn’t raised in 20 years and is not linked to inflation.

Potential breakthrough in brain-computer interface research

New research from Precision Neuroscience shows its brain-computer interface can record high-resolution signals without invasive surgery.

Claudio Cerchione, Hema Now

Hema Now: Episode 26: Highlights from the 2025 IMS Meeting

In this episode, Claudio Cerchione recaps the 2025 International Myeloma Society (IMS) Annual Meeting, highlighting key advances in treatment, the evolving research landscape, and more.

FTSE 100 hits new high as UK pharma stocks surge

UK pharma and healthcare stocks drive FTSE 100 to a record high, led by AstraZeneca, as trade policy shifts boost investor confidence.

Month in pharma news, explained

Month in pharma news, explained – September 2025

Read this month’s pharma news roundup, featuring AI in healthcare risks, GLP-1 drug trials beyond obesity and Trump’s US tariffs.

Digital hospital popping out of phone

NHS Online digital hospital to launch by 2027

England’s NHS is launching NHS Online, a fully digital hospital, to speed up specialist appointments, cut wait times and improve care access.

Two US flags

US pharma tariffs: Trump threatens 100% on imports

Donald Trump has threatened sweeping new trade measures on the pharma sector unless manufacturers commit to producing in the US.

Gold coins on blue background

Sanofi commits $625m to Sanofi Ventures

Sanofi has committed $625m to its corporate venture capital arm, Sanofi Ventures, for funding biotech and digital health companies.

Two doctors discussing social media, with one holding an iPad

Social media: What pharma needs to know in 2025

From listening in real time to outpacing the algorithm, these four trends show how marketers can succeed on social media in 2025.

People shaking hands on a merger

Pfizer enters obesity race with $4.9bn Metsera deal

Pfizer is claiming a space in the global obesity market as it announces plans to acquire weight loss drug developer Metsera for $4.9bn.